Navigation Links
First successful treatment of pediatric cerebral palsy with autologous cord blood
Date:5/23/2013

Bochum's medics have succeeded in treating cerebral palsy with autologous cord blood. Following a cardiac arrest with severe brain damage, a 2.5 year old boy had been in a persistent vegetative state with minimal chances of survival. Just two months after treatment with the cord blood containing stem cells, the symptoms improved significantly; over the following months, the child learned to speak simple sentences and to move. "Our findings, along with those from a Korean study, dispel the long-held doubts about the effectiveness of the new therapy", says Dr. Arne Jensen of the Campus Clinic Gynaecology. Together with his colleague Prof. Dr. Eckard Hamelmann of the Department of Paediatrics at the Catholic Hospital Bochum (University Clinic of the RUB), he reports in the journal "Case Reports in Transplantation".

The parents searched the literature for treatment options

At the end of November 2008, the child suffered from cardiac arrest with severe brain damage and was subsequently in a persistent vegetative state with his body paralysed. Up to now, there has been no treatment for the cause of what is known as infantile cerebral palsy. "In their desperate situation, the parents searched the literature for alternative therapies", Arne Jensen explains. "They contacted us and asked about the possibilities of using their son's cord blood, frozen at his birth."

"Threatening, if not hopeless prognosis"

Nine weeks after the brain damage, on 27 January 2009, the doctors administered the prepared blood intravenously. They studied the progress of recovery at 2, 5, 12, 24, 30, and 40 months after the insult. Usually, the chances of survival after such a severe brain damage and more than 25 minutes duration of resuscitation are six per cent. Months after the severe brain damage, the surviving children usually only exhibit minimal signs of consciousness. "The prognosis for the little patient was threatening if not h
'/>"/>

Contact: Eckard Hamelmann
info@kinderklinik-bochum.de
Ruhr-University Bochum
Source:Eurekalert

Page: 1 2

Related biology news :

1. Gym class reduces probability of obesity, study finds for first time
2. First Atlanta Science Festival set for 2014
3. Bowman Design Group is first US company awarded German FAMAB Sustainable Company certification
4. European support for the first network of research and training in political ecology
5. CNIO researchers capture the replication of the human genome for the first time
6. Odd experiments by Americas first physiologist shed light on digestion
7. Aware, Inc. Reports First Quarter 2013 Financial Results
8. Olympic Coast Sanctuary report is first step in addressing effects of climate change
9. First genetic factor in prostate cancer prognosis identified
10. First tests of old patent medicine remedies from a museum collection
11. Student named universitys first Lawrence scholar, researching at national laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Research and Markets ( ... the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 ... the global digital media watermarking and fingerprinting ... piracy by securely and invisibly embedding identifiable ...
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ... new funding to expand its team and bring LaunchKey ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... addition of the "Global Chemical Sensor Market ... http://photos.prnewswire.com/prnh/20130307/600769 One ... increasing demand for medical sensors in biomedical applications. ... for quick and correct diagnosis during surgical procedures. ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... X syndrome (FXS) is the most common hereditary form ... from attention deficit and/or hyperactivity disorder (ADHD), which complicates ... medication such as Ritalin is often successfully used to ... it is effective in children with mental retardation, it ...
... choose the nesting location of their first breeding season has ... a new University of Maryland/National Zoo study of the ... in their first year may help determine where they breed ... significantly affect the population as climate change makes their winter ...
... January 2001, the world held its breath when the tanker ... and began breaking up in the heart of one of ... the Galapagos Islands. At risk were vast numbers of ... Charles Darwin that contributed to his landmark theory of evolution ...
Cached Biology News:Effective ADHD treatment found for children with fragile X syndrome 2Early environment may be key to determining bird migration location 2Early environment may be key to determining bird migration location 3First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 2First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 3First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 4
(Date:12/24/2014)... 23, 2014 Vermillion, Inc. (Nasdaq:   ... disease, announced today that investors including Oracle Investment ... LLC and several Vermillion directors have agreed to ... Vermillion,s common stock and warrants to purchase unregistered ... placement.  Under the terms of ...
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich Corporation ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements ... expired on December 22, 2014, thereby completing the ... for the acquisition of the Company by Merck ... clearance satisfies another condition to closing the transaction, ...
(Date:12/24/2014)... and NEW YORK , Dec. 23, ... open-label pilot study of mazindol in children with attention ... Therapy in December 2014 . The ... children with attention deficit/hyperactivity disorder" ( Konofal et al, ... Dec 1;8:2321-2332. eCollection 2014 ) shows that mazindol ...
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... , Shareholders ... , Call by over 18% of ... Significant funding shortfall identified in the Progen merger proposal , ... Late last week Progen Pharmaceuticals Limited (ASX: PGL) responded to the requisitioning ...
... Clinics of Excellence, LLC, the nation,s only physician-driven ... its 62nd comprehensive Evidence-Based Treatment Protocol covering 11 ... 4th Annual Community Oncology Conference today. "Our 200+ ... to launch the protocols across its network in ...
... Feb. 6 Stereotaxis, Inc. (Nasdaq:, STXS ) ... for the,fourth quarter and full year ended December 31, ... The Company will host a conference call and,webcast on ... to discuss,the Company,s fourth quarter results and current corporate ...
Cached Biology Technology:Cytopia and Other Progen Shareholders Maintain Call for Meeting 2Cytopia and Other Progen Shareholders Maintain Call for Meeting 3Cytopia and Other Progen Shareholders Maintain Call for Meeting 4Cancer Clinics of Excellence (CCE) Releases 62nd Evidence-Based Treatment Protocol 2Stereotaxis Announces Fourth Quarter and Full Year 2008 Earnings Release Date and Conference Call 2
Standard Fluka For microscopy (Bact., Hist.)...
Request Info...
... description: Aminopropylsilane is perhaps ... slide chemistry for microarray ... Slides for Microarrays provide ... substrate for printing PCR ...
Special grade: for electrophoresis...
Biology Products: